Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
NetScientific PLC on Monday said its portfolio company ProAxsis Ltd secured £1.8 million in investment.
The London-based deep tech and life sciences venture capital investor holds a 91% stake in ProAxsis, and since September its post-investment fair value has more than doubled to £8.0 million from £3.5 million.
The funding was provided by a cohort of private investors led by NetScientific’s wholly owned corporate finance firm EMV Capital Ltd.
ProAxsis, a Belfast-based respiratory disease diagnostics company, will use the proceeds to fund working capital requirements and develop its product range of immunoassays and point-of-care tests.
A total of £211,000 was raised from new investors, with a further £36,000 coming from the exercise of warrants granted to existing investors in connection with convertible loan notes.
The conversion of these notes were valued at £455,000, meanwhile the conversion of loans from NetScientific were valued at £776,000.
In addition to this, ProAxsis has provided for an additional sum of up to £289,000 to be raised on the same terms as the existing new investors.
NetScientific Chief Executive Officer Ilian Iliev said: ‘These investments demonstrate strong financial support as ProAxsis develops its offering to the respiratory disease market, whilst it explores options for a potential sale to a new strategic owner.’
NetScientific shares were up 4.1% to 60.35 pence each in London on Monday morning.
Copyright 2024 Alliance News Ltd. All Rights Reserved.